- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BiomX files to sell 120.15M warrants for holders | 1 | Seeking Alpha | ||
| 23.04. | BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) | 2 | GlobeNewswire (USA) | ||
| 18.04. | BiomX Announces the Appointment of Susan Blum to its Board of Directors | 3 | GlobeNewswire (USA) | ||
| 15.04. | BiomX Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 04.04. | BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 04.04. | BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure | 77 | GlobeNewswire (Europe) | CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies... ► Artikel lesen | |
| 04.04. | BiomX Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 04.04. | BiomX Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 04.04. | Earnings call: BiomX reports progress on BX004 and BX211, secures funding | 1 | Investing.com | ||
| 03.04. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.04. | BiomX GAAP EPS of -$0.51 | 1 | Seeking Alpha | ||
| 03.04. | BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 59 | GlobeNewswire (Europe) | Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline Closed concurrent $50 million financing to support BX004 and BX211 programs... ► Artikel lesen | |
| 01.04. | BiomX Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 27.03. | BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024 | 2 | GlobeNewswire (USA) | ||
| 20.03. | OrbiMed executives acquire $499,984 worth of BiomX Inc. warrants | 2 | Investing.com | ||
| 18.03. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing | 100 | GlobeNewswire (Europe) | Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis ("CF") patients... ► Artikel lesen | |
| 06.03. | Phage therapy co BiomX merges with APT, raises $50m | 2 | Globes | ||
| 06.03. | Why Is BiomX (PHGE) Stock Up 147% Today? | 5 | InvestorPlace | ||
| 06.03. | BiomX acquires fellow bacteria-killing virus company Adaptive Phage to accelerate phase 2 plans | 2 | FierceBiotech |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,65 | +2,39 % | Moderna Aktie zieht BioNTech davon - Zahlen besser als erwartet | BioNTechs großer US-Konkurrent Moderna hat am Donnerstag Quartalszahlen vorgelegt - und der Aktienkurs des Biotech-Unternehmens reagiert äußerst positiv. Aktuell gewinnt der Titel an der US-Techbörse... ► Artikel lesen | |
| MORPHOSYS | 66,10 | -0,15 % | MorphoSys: Effekte der Novartis-Übernahmeofferte sorgen für hohen Quartalsverlust | Übernahmekandidat MorphoSys schließt das erste Quartal 2024 mit einem Verlust im fortgeführten Geschäft von 311 Millionen Euro ab nach 32,2 Millionen Euro Minus im Vorjahresquartal. Der Umsatz steigt... ► Artikel lesen | |
| AMGEN | 257,15 | +0,16 % | Amgen Aktie: Revolutionäre Therapie gegen Schilddrüsenaugenerkrankung | Der Biotechnologie-Konzern Amgen hat kürzlich Pläne bekannt gegeben, eine Zulassung für sein neuestes Medikament zur Behandlung einer schweren Autoimmunerkrankung bei der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 10,680 | -2,38 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grants Under Inducement Plan | PLYMOUTH MEETING, Pa., May 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,433 | +7,18 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights | RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base
Focused externally funded... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,916 | +1,91 % | Impulse setzen - Cardiol Therapeutics, Evotec, Redcare Pharmacy Aktie | Für risikobewusste Anleger ist die Pharma- und Biotechsparte ein lukrativer Markt für Investitionen. Die Branche wächst seit Jahrzehnten und auch für die kommenden Jahre wird mit einem Wachstum von... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,656 | +6,84 % | APEV, PACB and BILI are among premarket gainers | ||
| FIBROGEN | 1,038 | -1,47 % | FibroGen, Inc.: FibroGen to Report First Quarter 2024 Financial Results | ||
| ALLAKOS | 1,074 | +8,59 % | Allakos Inc.: Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative... ► Artikel lesen | |
| ORPHAZYME | 142,50 | +10,89 % | Nasdaq Copenhagen A/S: Orphazyme A/S - reduction of share capital by reduction of face value | The changes below will take effect on Nasdaq Copenhagen as per 12 January 2024.
ISIN DK0062502894
--------------------------------------------------------------------
Name:... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,904 | +1,45 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback... ► Artikel lesen | |
| VAXCYTE | 59,00 | +4,42 % | Vaxcyte, Inc.: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants | -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 2,515 | +3,93 % | 11 Analysts Assess Taysha Gene Therapies: What You Need To Know | ||
| VERRICA PHARMACEUTICALS | 6,285 | -4,26 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA | NCE status provides a minimum of five years of regulatory exclusivity The Company's U.S. patents and pending patent applications related to YCANTH are projected to expire between 2034 and 2041, excluding... ► Artikel lesen | |
| QIAGEN | 39,585 | +1,29 % | Qiagen bekräftigt Prognose für 2024 - erste Expertenstimmen | Das Biotech-Unternehmen Qiagen meldet für das erste Quartal 2024 einen Umsatzrückgang von 485,4 Millionen Dollar auf 458,8 Millionen Dollar. Das Betriebsergebnis ist leicht gefallen und liegt bei 94... ► Artikel lesen |
BIOMX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,016 (-3,51 %) liegt der Kurs bei 0,429 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
